{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:32:03Z","timestamp":1789104723505,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In 2022, the American Food and Drug Administration and the European Medicines Agency approved [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 (PLUVICTO\u2122, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membrane antigen (PSMA) ligands in metastatic prostate cancer. Theranostics require appropriate patients to be identified by positron emission tomography (PET) prior to radionuclide therapy, usually employing [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11. Alternatively, several\n                      <jats:sup>18<\/jats:sup>\n                      F-labelled PSMA-PET tracers are available and may increasingly replace\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labelled compounds, with respect to their image quality, availability and other practical advantages. However, alternative tracers may differ in uptake behaviour, and their comparability with regard to patient selection for [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA therapy has not yet been established. Here, we analysed whether tumour-to-background ratios determined by PET using the\n                      <jats:sup>18<\/jats:sup>\n                      F-labelled PSMA-specific radiopharmaceutical [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyL were comparable to those determined by PET using [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      No differences could be observed between [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11-PET and [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyL-PET regarding tumour-to-liver ratios or tumour-to-mediastinum ratios (e. g. tumour-to-liver ratios using maximum SUV of the tumour lesion for ultra-high definition reconstructed PET images with a median of 2.5 (0.6\u20139.0) on [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11-PET vs. 2,0 (0.6\u201311.4) on [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyL-PET). However, significant differences were observed in terms of contrast-to-noise ratios, thereby demonstrating the better image quality obtained with [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyL-PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our data showed that [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyl-PET and [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11-PET provide comparable tumour-to-liver and tumour-to-mediastinum ratios. Therefore, a tumour uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyL above the liver background, like using [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PSMA-11, can be considered as equally suitable for defining PSMA-positivity by a semiquantitative assessment based on the liver background, e. g. prior to radioligand therapy with\n                      <jats:sup>177<\/jats:sup>\n                      Lu-labelled PSMA ligands. In addition, our data suggest a tending advantage of [\n                      <jats:sup>18<\/jats:sup>\n                      F]F-DCFPyL in terms of lesion detectability.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-023-01033-x","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:02:22Z","timestamp":1695211342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0026-824X","authenticated-orcid":false,"given":"Jan","family":"Heilinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Weindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin Sabine","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Krapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schom\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"3","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1033_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"1033_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"3","key":"1033_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cpet.2021.03.003","volume":"16","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seifert R, Rahbar K, Afshar-Oromieh A. Prostate cancer theranostics: from target description to imaging. PET Clin. 2021;16(3):383\u201390.","journal-title":"PET Clin"},{"issue":"5","key":"1033_CR5","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62(5):596\u2013604.","journal-title":"J Nucl Med"},{"issue":"5B","key":"1033_CR6","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927\u201335.","journal-title":"Anticancer Res"},{"issue":"1","key":"1033_CR7","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1033_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637\u201340.","journal-title":"Urology"},{"issue":"7","key":"1033_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","volume":"59","author":"DS O'Keefe","year":"2018","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, Heston WDW. A Perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med. 2018;59(7):1007\u201313.","journal-title":"J Nucl Med"},{"issue":"3","key":"1033_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2967\/jnmt.122.263814","volume":"50","author":"EE Parent","year":"2022","unstructured":"Parent EE, Savir-Baruch B, Gayed IW, Almaguel F, Chin BB, Pantel AR, et al. (177)Lu-PSMA therapy. J Nucl Med Technol. 2022;50(3):205\u201312.","journal-title":"J Nucl Med Technol"},{"key":"1033_CR11","unstructured":"US Food and Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer. Accessed 5 Feb 2023."},{"key":"1033_CR12","unstructured":"European Medicines Agency. Pluvicto (177Lu)Lutetiumvipivotid tetraxetan - \u00dcbersicht \u00fcber Pluvicto und warum es in der EU zugelassen ist. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pluvicto-epar-medicine-overview_de.pdf. Accessed 11 May 2023."},{"issue":"2","key":"1033_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167\u201372.","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"1033_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"issue":"4","key":"1033_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565\u201374.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"1033_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575\u201384.","journal-title":"Mol Imaging Biol"},{"issue":"12 Suppl","key":"1033_CR17","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F","volume":"80","author":"YE Erdi","year":"1997","unstructured":"Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(12 Suppl):2505\u20139.","journal-title":"Cancer"},{"issue":"3","key":"1033_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"4","key":"1033_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2967\/jnumed.121.262290","volume":"63","author":"F Dietlein","year":"2022","unstructured":"Dietlein F, Kobe C, V\u00e1zquez SM, Fischer T, Endepols H, Hohberg M, et al. An (89)Zr-labeled PSMA tracer for PET\/CT imaging of prostate cancer patients. J Nucl Med. 2022;63(4):573\u201383.","journal-title":"J Nucl Med"},{"issue":"6","key":"1033_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58(6):947\u201352.","journal-title":"J Nucl Med"},{"issue":"2","key":"1033_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2967\/jnumed.119.229542","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, et al. An (18)F-labeled PSMA ligand for PET\/CT of prostate cancer: first-in-humans observational study and clinical experience with (18)F-JK-PSMA-7 during the first year of application. J Nucl Med. 2020;61(2):202\u20139.","journal-title":"J Nucl Med"},{"issue":"2","key":"1033_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11307-020-01546-0","volume":"23","author":"F Dietlein","year":"2021","unstructured":"Dietlein F, Mueller P, Kobe C, Endepols H, Hohberg M, Zlatopolskiy BD, et al. [(18)F]-JK-PSMA-7 PET\/CT under androgen deprivation therapy in advanced prostate cancer. Mol Imaging Biol. 2021;23(2):277\u201386.","journal-title":"Mol Imaging Biol"},{"issue":"supplement 2","key":"1033_CR23","first-page":"1423","volume":"51","author":"JH Kim","year":"2010","unstructured":"Kim JH, Lee JS, Kim JS, Chung J-K, Lee MC, Lee DS. Physical performance comparison of Ga-68 and F-18 in small animal PET system. J Nuclear Med. 2010;51(supplement 2):1423.","journal-title":"J Nuclear Med."},{"issue":"1","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-019-0211-y","volume":"19","author":"G Ferreira","year":"2019","unstructured":"Ferreira G, Iravani A, Hofman MS, Hicks RJ. Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution. Cancer Imaging. 2019;19(1):23.","journal-title":"Cancer Imaging"},{"issue":"5","key":"1033_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"S Fanti","year":"2022","unstructured":"Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, et al. EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [(177)Lu]Lu-PSMA radioligand therapy. Eur Urol Oncol. 2022;5(5):530\u20136.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2967\/jnumed.119.234898","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Kobe C, Hohberg M, Zlatopolskiy BD, Krapf P, Endepols H, et al. Intraindividual comparison of (18)F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61(5):729\u201334.","journal-title":"J Nucl Med"},{"issue":"3","key":"1033_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","volume":"5","author":"L Evangelista","year":"2022","unstructured":"Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, et al. [(68)Ga]Ga-PSMA Versus [(18)F]PSMA positron emission tomography\/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature. Eur Urol Oncol. 2022;5(3):273\u201382.","journal-title":"Eur Urol Oncol."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-023-01033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-023-01033-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-023-01033-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:32:27Z","timestamp":1700310747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-023-01033-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1186\/s13550-023-01033-x","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Commission of the Faculty of Medicine of Cologne University has confirmed that no ethical approval is required. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All enrolled patients gave written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All enrolled patients gave written informed consent for the publication of this study and its accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.D. discloses research support from Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, SOFIE, Eisai and Novartis\/AAA; Speaker Honorary and\/or Advisory Boards fees from Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis\/AAA and Bayer Vital; Stock from Siemens Healthineers, Lantheus Holding; a patent pending for <sup>18<\/sup>F-PSMA-JK-7 (PSMA imaging tracer) (PSMA-PET imaging tracer).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"83"}}